APA (7th ed.) Citation

Starodub, A., Kim, S., Davar, D., Powderly, J., Hill, A., Yeku, O., . . . Kwatra, V. (2023). 1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. Annals of Oncology, 34, S628. https://doi.org/10.1016/j.annonc.2023.09.2173

Chicago Style (17th ed.) Citation

Starodub, A.N, et al. "1034P Phase I/II Dose Escalation and Dose Expansion Study of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab: Determination of Recommended Phase II Dose (RP2D) for Monotherapy." Annals of Oncology 34 (2023): S628. https://doi.org/10.1016/j.annonc.2023.09.2173.

MLA (9th ed.) Citation

Starodub, A.N, et al. "1034P Phase I/II Dose Escalation and Dose Expansion Study of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab: Determination of Recommended Phase II Dose (RP2D) for Monotherapy." Annals of Oncology, vol. 34, 2023, p. S628, https://doi.org/10.1016/j.annonc.2023.09.2173.